Insiders Buy: Director bought on Dec 17&18 during its down trend, qty 504,214 @ average price $16.81 total value $8.5M.
Director bought on Dec 18 & 21 when the price dropped down almost hit the resistance.
Trading Plan - Entry Rule; Higher high, higher low, bullish candle after higher low, entry if open higher than the previous day close $68.99 - Stop loss; not lower than the open price of previous day $67.12 - Target Price @ previous high $75.7 - Reward to Risk ratio 2.97
Trading Plan - Entry Rule; Bullish candle after price dipped down to the support line after close gap, entry if open higher than the previous day close $48.4 - Stop loss; not lower than the previous day low $47.34 - Target Price @ previous high $51.10 - Reward to Risk ratio 2.26
Trading Plan - Entry Rule; Break Resistant Line $73.80 - Stop loss; Previous day low $72.93 - Target Price @ previous high $78.63 - Reward to Risk ratio 4.82 Warning: Not guarantee the success :)
Trading Plan - Entry Rule; Break Resistant Line $34.5 - Stop loss; not below the expected throw back after break out not lower than $32.76 - Target Price $40.06, close gap - Reward to Risk ratio 3.38
Trading Plan - Entry Rule; Reversal pattern, bullish candle the if open price higher than previous day close $100.5 - Stop loss, half of the previous day price range $99.50 - Target Price 105.43, previous high - Reward to Risk ratio 5.41
It's too late to Put now, and too early to Call. So just wait and see which way it choose.
MAT is on downtrend in TF Week, but TF Day seem reversal to uptrend, break out the previous high. Will the next target be $30?
If the price hike up above 36.4, guess it will go up to hit 38.43 again. Wait and see.
HSIC indicated short term bearish after hit the highest,
Wait & see CTSH if continue bearish to the lower trading range or reversal.
Put with a condition of stop loss at 34.3, 1st target 32, next 30.8, and final goal 27.4.
The candles keep side way and flat due to the uncertainty whether or not FDA will approve a drug, Kyndrisa, If Kyndrisa is not approved, it will negatively impact BioMarin’s share price. However, if it is approved, Kyndrisa will result in high profits for the company. So wait and see.
Dec 11 AMZN candle had bearish pattern and trading was out of the uptrend trading range. Target @ $595, stop loss $650. If the candle is back to the uptrend trading zone, consider to call.